고과당식이 투여 랫드모델에서 홍삼과 상엽 복합투여에 대한 혈관염증 및 지방간염 억제 효과
Inhibitory Effect of Combination with Korean Red Gnseng and Morus Alba in High Fructose-induced Vascular Inflammation and Steatohepatitis
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
This study was designed to elucidate whether combination with Korean red ginseng and Morus alba L. (MPM), traditional treatment for diabetes, ameliorates on high fructose-induced steatohepatitis and vascular inflammation. Animals were divided into four groups; Control receiving tap water, fructose-fed, rosiglitazone-treated fructose-fed rats, and MPM-treated fructose-fed rats both receiving supplemented with 60% fructose (n=10). The MPM or rosiglitazone groups initially received a high-fructose diet alone for 8 weeks, with supplementation with MPM or rosiglitazone, peroxisome proliferators-activated receptor gamma (PPARγ) agonist, occurring during the final 6 weeks. Treatment with MPM significantly prevented the increase in c-reactive protein (CRP) levels in the high fructose group. MPM suppressed high fructose diet-induced vascular inflammation marker expression such as intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. MPM also reduced intima/media thickness of thoracic aorta. Histologic observation and oil red O staining demonstrated hepatic tissue damage and lipid accumulation were severe in high fructose group. Treatment with MPM ameliorated hepatic tissue morphology with minimized steatosis. In addition, MPM attenuated hepatitis by inhibition of monocyte chemoattractant protein-1 (MCP-1) expression. MPM-fed group showed lower serum GOT and GPT levels comparing with high fructose group. MPM and rosiglitazone (positive control) significantly decreased the size of epididymal adipocytes. Taken together, the administration of MPM inhibited high fructose-induced steatohepatitis and vascular inflammation. These results suggested that MPM is useful in the prevention or treatment of metabolic syndrome-related disorders such as fatty acid metabolism and vascular homeostasis.
Abstract
This study was designed to elucidate whether combination with Korean red ginseng and Morus alba L. (MPM), traditional treatment for diabetes, ameliorates on high fructose-induced steatohepatitis and vascular inflammation. Animals were divided into four groups; Control receiving tap water, fructose-fed, rosiglitazone-treated fructose-fed rats, and MPM-treated fructose-fed rats both receiving supplemented with 60% fructose (n=10). The MPM or rosiglitazone groups initially received a high-fructose diet alone for 8 weeks, with supplementation with MPM or rosiglitazone, peroxisome proliferators-activated receptor gamma (PPARγ) agonist, occurring during the final 6 weeks. Treatment with MPM significantly prevented the increase in c-reactive protein (CRP) levels in the high fructose group. MPM suppressed high fructose diet-induced vascular inflammation marker expression such as intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and E-selectin. MPM also reduced intima/media thickness of thoracic aorta. Histologic observation and oil red O staining demonstrated hepatic tissue damage and lipid accumulation were severe in high fructose group. Treatment with MPM ameliorated hepatic tissue morphology with minimized steatosis. In addition, MPM attenuated hepatitis by inhibition of monocyte chemoattractant protein-1 (MCP-1) expression. MPM-fed group showed lower serum GOT and GPT levels comparing with high fructose group. MPM and rosiglitazone (positive control) significantly decreased the size of epididymal adipocytes. Taken together, the administration of MPM inhibited high fructose-induced steatohepatitis and vascular inflammation. These results suggested that MPM is useful in the prevention or treatment of metabolic syndrome-related disorders such as fatty acid metabolism and vascular homeostasis.
참고문헌 (39)
- Georg, P., "Lipids and diabetes", J. Clin. Basic, 3, pp.159~162 (2000)
- Yoon, K. H., "Epidemic obesity and type 2 diabetes in Asia", LANCET, 368, pp.1681~1688, LANCET LTD
- Tay, S. S., "Effect of cognate human CD4+ Tcell and endothelial cell interactions upon chemokine production", Transplantatio, 78(7), pp.987~994 (2004)
- Uze, G., "Cytokines in juvenile dermatomyositis pathophysiology: potential and challenge", Curr. Opin. Rheumatol, 15(6), pp.691~697 (2003)
- Frostegard, J., "Mononuclear leukocytes exposed to oxidized low density lipoprotein secrete a factor that stimulates endothelial cells to express adhesion molecules", Atherosclerosis, 103, pp.213~219 (1993)
- Mes, Bouhle., M.A, "Peroxisome proliferator-activated receptors-from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease", J. Intern. Med, 263(1), pp.28~42 (2008)
- Li, J. J., "The role of inflammation in coronary artery calcification", Agening. Res. Rev, 6(4), pp.263~270 (2007)
- Matteoni, C. A., "Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
- Bugianesi, E., "Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma", Gastroenterology, 123, pp.134~140 (2002)
- Marrero, J. A., "NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States", Hepatology, 36, pp.1349~1354 (2002)
- Jun, D.W., "Non-alcoholic fatty liver disease", Korean J. Hepatol, 17, pp.S332~S336 (2011)
- Marchesini, G., "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", Hepatology, 37, pp.917~923 (2003)
- 홍민희, "산삼 배양근 추출물의 혈압강하 및 혈관이완 효과", Journal of the Korean Society for Applied Biological Chemistry, 51(2), pp.102~107 (2008), 한국응용생명화학회
- Mizuno, M., "Differences in immunomodulating effects between wild and cultured Panax ginseng", Biochem. Biophys. Res. Commun, 200, pp.1672~1678 (1994)
- 권기록, "Identification and Analysis of Differentially Expressed Genes in Mountain Cultivated Ginseng and Mountain Wild Ginseng", Journal of Acupuncture & Meridian Studies, 4(2), pp.123~128 (2011), 세계약침학회
- Liu, C. X., "Recent advances on ginseng research in China", J. Ethnopharmacol, 36, pp.27~38 (1992)
- Kitts, D., "Efficacy and safety of ginseng", Public. Health. Nutr, 3, pp.473~485 (2000)
- Enkhmaa, B., "Mulberry (Morus alba L.) leaves and their major flavonol quercetin 3-(6-malonylglucoside) attenuate atherosclerotic lesion development in LDL receptor-deficient mice", J. Nutr, 135, pp.729~734 (2005)
- Miyahara, C., "Inhibitory effects of mulberry leaf extract on postprandial hyperglycemia in normal rats", J. Nutr. Sci. Vitaminol, 50, pp.161~164 (2004)
- Lee, Y. J., "Hypotensive, hypolipidemic, and vascular protective effects of Morus alba L. in rats fed an atherogenic diet", Am. J. Chin. Med, 39, pp.39~52 (2011)
- 박승하, "Prevalence and risk factors of non-alcoholic fatty liver disease among Korean adults", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 21, pp.138~143, BLACKWELL PUBLISHING
- Elliott, S. S., "Fructose, weight gain, and the insulin resistance syndrome", Am. J. Clin. Nutr, 76, pp.911~922 (2002)
- Hwang, I. S., "Fructose-induced insulin resistance and hypertension in rats", Hypertension, 10, pp.512~516 (1987)
- Sánchez-Lozada, L. G., "Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats", Am. J. Physiol. Renal. Physiol., 292, pp.423~429 (2007)
- Feingold, K. R., "Role of cytokines in inducing hyperlipidemia", Diabetes, 41, pp.97~101 (1992)
- Stenvinkel, P., "Elevated interleukin-6 predicts progressive carotid artery atherosclerosis in dialysis patients: Association with Chlamydia pneumoniae seropositivity", Am. J. Kidney. Dis, 39, pp.274~282 (2002)
- Duprez, D. A., "Relationship between Creactive protein and arterial stiffness in an asymptomatic population", J. Hum. Hypertens, 19, pp.515~519 (2005)
- Hommels, M.J, "C-reactive protein, atherosclerosis and kidney function in hypertensive patients", J. Hum. Hypertens, 19, pp.521~526 (2005)
- Quagliaro, L., "LDL receptor but not apolipoprotein E deficiency increases diet-induced obesity and diabetes in mice", Am. J. Physiol. Endocrinol. Metab, 282, pp.207~214 (2002)
- Diehl, A.M, "Nonalcoholic steatohepatitis", Semin. liver. dis, 19, pp.220~229 (1999)
- Akyuz, F., "The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease", Dig. Dis. Sci, 52, pp.2359~2367 (2007)
- Neuschwander-Tetri, B. A., "Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone", Hepatology, 38, pp.1008~1017 (2003)
- Belfort, R., "A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis", N. Engl. J. Med., 335, pp.2297~2307 (2006)
- Promrat, K., "A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis", Hepatology, 39, pp.188~196 (2004)
- Park, Y., "A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis", Hepatology, 39, pp.188~196 (2004)
- Fortez, M., "Short-term overexpression of a constitutively active form of AMPK-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver", Diabetes, 54, pp.1331~1339 (2005)
- Nielsen, S., "Splanchnic lipolysis in human obesity", J. Clin. Invest, 113, pp.1582~1588 (2004)
- Furukawa, S., "Increased oxidative stress in obesity and its impact on metabolic syndrome", J. Clin. Invest, 114, pp.1752~1761 (2004)